WELLESLEY, Mass., Aug. 19 /PRNewswire/ -- Xceed Molecular, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced that R&D Magazine has selected the company’s Ziplex System as a recipient of the magazine’s prestigious R&D 100 Award. Called the Oscars of Invention by The Chicago Tribune, the 45-year-old R&D 100 Award, is according to R&D, “a mark of excellence known to industry, government, and academia as proof that the product is one of the most innovative ideas of the year.” Xceed’s Ziplex System - comprising an automated hybridization workstation, Autograph and Xpress Chip(TM) consumable arrays, reagents, and automated analysis/reporting software - is the first integrated system for automated gene-expression analysis.
“We are honored to become a member of this elite group of R&D 100 award winners, whose inventions have contributed so much to society,” said Xceed President and CEO, David Deems. “This award is a wonderful testament to the talented team of designers, hardware and software engineers, microarray and biochemistry experts who have worked tirelessly over the years to take a complex, expensive, and time-consuming process - gene-expression analysis - and turn it into a simple, reproducible, and affordable one, where results remain consistent even when samples are run by different people, at different times, or in different sites.”
As translational medicine moves from the research laboratory to the clinical laboratory, technology that is affordable, reliable, and easy to operate will be critical. The translational process refines a gene-expression signature from hundreds of genes identified in the research stage to the 10 to 150 genes that comprise the final diagnostic assay. Increasingly, investigators are concerned that experiments conducted at different points in time, at multiple locations, or by multiple users may not be comparable due to inherent variability in analytical technology platforms and methodologies. In addition, with the growing amount of data generated from these studies, investigators need guidance and assistance in ensuring quality control in data collection, sample integrity, and analysis.
Designed to make routine molecular diagnostics easy, reproducible, and affordable to serve the rigorous performance and quality-control needs of both clinical research and clinical-diagnostic settings, the Ziplex System is rapidly becoming the system of choice for the nation’s leading institutions performing translational research. The system incorporates turnkey functionality and significant advances in automation, array format, fluidics, parallel sample processing, and analytics to minimize complexity, user interaction, and variability between users and sites.
About Xceed Molecular (www.XceedMolecular.com)
Xceed’s vision is to advance molecular diagnostics by successfully translating novel multiplex tests into routine clinical practice and to create robust diagnostic solutions to improve disease outcomes. Our products comprise the Ziplex System for automated gene-expression analysis (available in the US and Canada for research use only), gene expression services, customized arrays - Autograph Chips, and pre-configured arrays - Xpress Chips. Xceed is also developing multiplexed genomic tests for the Ziplex platform, both internally and with strategic partners. Xceed’s R&D and manufacturing are headquartered in Toronto, Ontario, with executive offices in Wellesley, Massachusetts.
CONTACT: Caroline Grossmam, +1-781-771-5579, or
caroline.grossman@gmail.com, for Xceed Molecular; or Company: Susan Josey
of Xceed Molecular, +1-972-317-8948, or sjosey@xceedmolecular.com
Web site: http://www.xceedmolecular.com//
